BRAF and lung carcinoma: NGS lung cancer panel was negative for mutations in ALK, ATK1, BRAF, CDK4, CTNNB1, DDR2, EGFR, FGFR2, FGFR3, HER2, HER3, HER4, JAK2, JAK3, KRAS, MAP2K1, MET, NRAS, PIK3CA, ROS1, and rearrangements in ALK, BRAF, FGFR3, NTRK, RET, and ROS1.